Seres Therapeutics, Inc. (NASDAQ:MCRB) – Analysts at Leerink Swann upped their Q3 2017 earnings estimates for shares of Seres Therapeutics in a research report issued to clients and investors on Thursday. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($0.23) for the quarter, up from their prior estimate of ($0.73). Leerink Swann also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($2.30) EPS, FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($2.24) EPS.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright lifted their price objective on Seres Therapeutics from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.17.
Seres Therapeutics (NASDAQ:MCRB) opened at 13.56 on Monday. The firm has a 50-day moving average of $12.20 and a 200-day moving average of $10.57. The company’s market capitalization is $547.69 million. Seres Therapeutics has a one year low of $8.85 and a one year high of $15.09.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.70) earnings per share.
Several large investors have recently modified their holdings of MCRB. Renaissance Technologies LLC raised its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock valued at $3,963,000 after buying an additional 103,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after buying an additional 103,456 shares during the period. Spark Investment Management LLC acquired a new stake in shares of Seres Therapeutics during the first quarter valued at $613,000. JPMorgan Chase & Co. raised its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the period. Finally, American Century Companies Inc. acquired a new stake in shares of Seres Therapeutics during the first quarter valued at $447,000. 75.31% of the stock is currently owned by institutional investors and hedge funds.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with our FREE daily email newsletter.